W W Parmley. Show Affiliations »
Abstract
Entities: Disease Species
Mesh： See more » Adrenergic beta-Antagonists/therapeutic useAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors/therapeutic useAnimalsCytokines/antagonists & inhibitorsCytokines/metabolismDigoxin/therapeutic useDisease Models, AnimalDiuretics/therapeutic useEndothelins/antagonists & inhibitorsEtanerceptHeart Failure/drug therapyHeart Failure/metabolismHumansImmunoglobulin G/therapeutic useImmunosuppressive Agents/therapeutic useMiceMice, TransgenicNeprilysin/antagonists & inhibitorsRandomized Controlled Trials as TopicReceptors, Tumor Necrosis Factor/therapeutic useSpironolactone/therapeutic useTumor Necrosis Factor-alpha/antagonists & inhibitorsTumor Necrosis Factor-alpha/metabolism
Substances： See more » Adrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCytokinesDiureticsEndothelinsImmunoglobulin GImmunosuppressive AgentsReceptors, Tumor Necrosis FactorTumor Necrosis Factor-alphaSpironolactoneDigoxinNeprilysinEtanercept
Year: 2001 PMID： 11273985 DOI： 10.1161/01.cir.103.12.1611
Source DB: PubMed Journal: Circulation ISSN： 0009-7322 Impact factor: 29.690